Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Chung-Hyo Kang"'
Autor:
Yeongrin Kim, Da Yeon Lee, Ji U Choi, Jin Song Park, So Myoung Lee, Chung Hyo Kang, Chi Hoon Park
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising modality for anti-cancer treatment. Its efficacy is quite remarkable in hematological tumors. Owing to their excellent clinical results, gene- modified cell therapies,
Externí odkaz:
https://doaj.org/article/60f107242f88406f9df7e3ef154b596f
Autor:
Minsung Kim, Suhkneung Pyo, Chung Hyo Kang, Chong Ock Lee, Heung Kyoung Lee, Sang Un Choi, Chi Hoon Park
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198347 (2018)
Gastric cancer is a malignancy that has a high mortality rate. Although progress has been made in the treatment of gastric cancer, many patients experience cancer recurrence and metastasis. Folate receptor 1 (FOLR1) is overexpressed on the cell surfa
Externí odkaz:
https://doaj.org/article/9ea7f921dc354f5faa19662885bab7d9
Autor:
Hyun-Il Cho, Chung-Hyo Kang, Sang-Eun Lee, In-Sil Song, Jung-Min Ha, Hyun-Jung Sohn, Tai-Gyu Kim
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8241d31c92472266466e49ab53b1f8c7
https://doi.org/10.1136/jitc-2022-sitc2022.0250
https://doi.org/10.1136/jitc-2022-sitc2022.0250
Publikováno v:
Anticancer Research. 41:1811-1819
Background/aim Glioblastoma is the most common cancer among primary brain tumors, however, its prognosis and treatment advances are very poor. Here, we investigated whether c-Met, FOLR1, and AXL proteins are promising targets for chimeric antigen rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d17acefff7ce7b769b1d30f77dbdf87c
https://doi.org/10.21873/anticanres.14947
https://doi.org/10.21873/anticanres.14947
Autor:
Hyun-Il Cho, Chung-Hyo Kang, Sang-Eun Lee, Mi-So Kim, Bo-Ra Lim, Jung-Min Ha, Hyun-Jung Sohn, Tai-Gyu Kim
Publikováno v:
Cancer Research. 83:1788-1788
Chimeric antigen receptor (CAR)-engineered adoptive cell therapy has demonstrated a feasible, attractive “off-the-shelf” approach against various malignancies. Success of CAR-engineered cell therapy depends primarily on providing optimized costim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3cc3fe20547fd70bb726a69abb9aecd
https://doi.org/10.1158/1538-7445.am2023-1788
https://doi.org/10.1158/1538-7445.am2023-1788
Autor:
Heung Kyoung Lee, Chung Hyo Kang, Hye Gwang Jeong, Chi Hoon Park, Chang-Soo Yun, Sunjoo Ahn, Sang Un Choi, You Hwa Son
Publikováno v:
Anticancer Research. 40:4929-4935
Background Mutations in the isocitrate dehydrogenase 1 (IDH1) gene are frequently found in various cancer types. IDH1 mutants produce 2-hydroxyglutarate (2-HG), an oncometabolite, from alpha-ketoglutarate (α-KG). This 2-HG plays a key role in tumori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c787f79a41c454d1091c1c9cd2b1bd6
https://doi.org/10.21873/anticanres.14496
https://doi.org/10.21873/anticanres.14496
Publikováno v:
Cancers
Volume 13
Issue 22
Cancers, Vol 13, Iss 5738, p 5738 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5738, p 5738 (2021)
Simple Summary c-Met is known to be overexpressed in gastric cancers. Here, we developed anti-c-Met CAR T cell and measured its anti-tumor efficacy in vitro and in vivo. Our anti c-Met CAR T cells have shown selective killing of c-Met overexpressed g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d2bba053488e77b1703929a0b7fd970
Autor:
Hyun-Il Cho, Chung-Hyo Kang, Sang-Eun Lee, In-Sil Song, Jung-Min Ha, Seon-Duk Lee, Hyun-Jung Sohn, Tai-Gyu Kim
Publikováno v:
Cancer Research. 82:5506-5506
Adoptive transfer of immune killer cells genetically engineered to express chimeric antigen receptors (CARs) has demonstrated a feasible and effective approach against numerous types of cancers. Among the killer cells, γδT cells possessing a wide r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1272a05a45f6a60873d27e76418f447a
https://doi.org/10.1158/1538-7445.am2022-5506
https://doi.org/10.1158/1538-7445.am2022-5506
Autor:
Yeongrin Kim, Jong Yeon Hwang, Hye Gwang Jeong, Chi Hoon Park, Sang Un Choi, So Myoung Lee, Chung Hyo Kang
Publikováno v:
ACS synthetic biology. 9(5)
Despite the excellent efficacy of chimeric antigen receptor (CAR T) cell therapy, concerns about its safety have been constantly raised. The side effects of CAR T cells result from an aberrantly upregulation of CAR T cell activity. Therefore, it is c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c33ba94de40c002db3d2551c9cc969b7
https://pubmed.ncbi.nlm.nih.gov/32352759
https://pubmed.ncbi.nlm.nih.gov/32352759
Publikováno v:
Biochemical and Biophysical Research Communications. 505:542-547
Recently, proteolysis targeting chimera (PROTAC) technology is highlighted in drug discovery area as a new therapeutic approach. PROTAC as a heterobifunctional molecule is comprised of two ligands, which recruit target protein and E3 ligase, respecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c158f5e3d87fc5196daa918444bd6a9
https://doi.org/10.1016/j.bbrc.2018.09.169
https://doi.org/10.1016/j.bbrc.2018.09.169